Groups | Moments of follow-up | |||||
---|---|---|---|---|---|---|
Baseline, n = 180 | 4 months, n = 158 | 8 months n = 153 | 12 months,* n = 146 | p-value1 | p-value2 | |
MMSE ± SD** | ||||||
Municipality | ||||||
Stimulation (n = 103) | 22.9 ± 4.6 | 22.1 ± 5.0 | 22.9 ± 4.5 | 22.6 ± 5.2 | 0.15 | 0.017 |
Standard care (n = 77) | 23.5 ± 4.3 | 23.8 ± 4. | 24.4 ± 4.0 | 23.9 ± 4.3 | ||
Drug | ||||||
Donepezil (n = 90) | 23.2 ± 4.2 | 23.3 ± 4.5 | 23.8 ± 4.3 | 23.0 ± 4.9 | 0.31 | 0.21 |
Placebo n = 90 | 23.1 ± 4.1 | 22.9 ± 4.8 | 23.4 ± 4.3 | 23.3 ± 4.8 | ||
Clock Drawing Test ± SD** | ||||||
Municipality | ||||||
Stimulation | 2.9 ± 1.2 | 2.9 ± 1.1 | 2.8 ± 1.1 | 3.0 ± 1.1 | 0.21 | 0.071 |
Standard care | 2.8 ± 1.2 | 3.0 ± 1.2 | 3.1 ± 1.1 | 3.1 ± 1.1 | ||
Drug | ||||||
Donepezil | 2.9 ± 1.2 | 2.8 ± 1.2 | 2.8 ± 1.2 | 3.0 ± 1.0 | 0.56 | 0.26 |
Placebo | 2.8 ± 1.1 | 3.0 ± 1.1 | 3.0 ± 1.0 | 3.1 ± 1.1 | ||
ADAS-cog ± SD** | ||||||
Municipality | ||||||
Stimulation | 18.9 ± 8.7 | 18.5 ± 8.4 | 17.0 ± 9.1 | 16.8 ± 8.5 | 0.23 | 0.11 |
Standard care | 17.4 ± 7.0 | 16.1 ± 6.9 | 15.7 ± 8.2 | 15.9 ± 8.0 | ||
Drug | ||||||
Donepezil | 18.6 ± 7.6 | 17.7 ± 7.8 | 16.3 ± 8.8 | 16.3 ± 8.4 | 0.59 | 0.24 |
Placebo | 17.9 ± 8.4 | 17.1 ± 7.9 | 16.5 ± 8.6 | 16.4 ± 8.2 |